We are pleased to invite investors and analysts to participate in our virtual event on Friday, 10 December 2021, highlighting new data from the tiragolumab Phase 2 Cityscape study including milestone overall survival data after 2.5 years of follow-up. The data will be presented at the congress scientific program, from Dec 8 - 11 2021. 16:00 - 16:50 CET / 15:00 - 15:50 GMT 10:00 - 10:50 am EST / 7:00 - 7:50 am PST The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CET on the day of the event. > click here   Agenda:   Welcome Karl Mahler, Head of Investor Relations   CITYSCAPE updated analysis: Tiragolumab + Tecentriq in 1L NSCLC Raymond Meng, M.D., Ph.D. - Global Development Leader Tiragolumab   Tiragolumab development overview Heather Stevens, MBA, MPH - Life Cycle Leader, Tiragolumab   Q&A Access to virtual event (pre-registration required) Please pre-register for our webinar here*. Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com. A replay of the webcast will be available via > ir.roche.com *privacy notice
Best regards, Karl Mahler Head of Investor Relations	Sabine Borngräber Investor Relations Officer
Roche Investor Relations
Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

 

get the latest news and updates to your inbox.